U.S. · BUSINESS · SCIENCE
May 31, 20221 min read, 271 words
Published: May 31, 2022 | 1 min read, 271 words
Buying 500 shares of Daiichi Sankyo stock 16 days before the company signed a lucrative licensing deal with AstraZeneca has a former AZ executive in the Securities and Exchange Commission's (SEC's) crosshairs. According to an SEC complaint, Hugues Joublin, Ph.D.—who was AZ’s glo...